MX360048B - Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico. - Google Patents

Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.

Info

Publication number
MX360048B
MX360048B MX2015009617A MX2015009617A MX360048B MX 360048 B MX360048 B MX 360048B MX 2015009617 A MX2015009617 A MX 2015009617A MX 2015009617 A MX2015009617 A MX 2015009617A MX 360048 B MX360048 B MX 360048B
Authority
MX
Mexico
Prior art keywords
crystalline forms
chlorophenoxy
cyano
carbonyl
hydroxy
Prior art date
Application number
MX2015009617A
Other languages
English (en)
Spanish (es)
Other versions
MX2015009617A (es
Inventor
Witschi Claudia
P Arend Michael
Min Park Jung
D Thompson Michael
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360048(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of MX2015009617A publication Critical patent/MX2015009617A/es
Publication of MX360048B publication Critical patent/MX360048B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2015009617A 2013-01-24 2014-01-23 Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico. MX360048B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361756361P 2013-01-24 2013-01-24
PCT/US2014/012780 WO2014116849A1 (en) 2013-01-24 2014-01-23 Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Publications (2)

Publication Number Publication Date
MX2015009617A MX2015009617A (es) 2016-04-20
MX360048B true MX360048B (es) 2018-10-19

Family

ID=50073508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009617A MX360048B (es) 2013-01-24 2014-01-23 Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.

Country Status (15)

Country Link
US (1) US9643928B2 (OSRAM)
EP (1) EP2951159B1 (OSRAM)
JP (1) JP6437456B2 (OSRAM)
KR (1) KR102233081B1 (OSRAM)
CN (1) CN105452227B (OSRAM)
AU (1) AU2014209319B2 (OSRAM)
CA (1) CA2899024C (OSRAM)
DK (1) DK2951159T3 (OSRAM)
ES (1) ES2694297T3 (OSRAM)
IL (1) IL240066B (OSRAM)
MX (1) MX360048B (OSRAM)
RU (1) RU2666144C2 (OSRAM)
SG (2) SG10202009266PA (OSRAM)
TW (1) TWI685487B (OSRAM)
WO (1) WO2014116849A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644336B1 (en) 2003-06-06 2011-01-19 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
SMT201800565T1 (it) 2012-07-16 2018-11-09 Fibrogen Inc Forme cristalline di un inibitore di prolil idrossilasi
BR112015001106B1 (pt) 2012-07-16 2021-11-09 Fibrogen, Inc Métodos para a produção de compostos de isoquinolina
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
JP6437456B2 (ja) 2013-01-24 2018-12-12 フィブロジェン インコーポレイテッド ｛［１−シアノ−５−（４−クロロフェノキシ）−４−ヒドロキシ−イソキノリン−３−カルボニル］−アミノ｝−酢酸の結晶形態
WO2014197660A1 (en) 2013-06-06 2014-12-11 Fibrogen, Inc. Pharmaceutical formulations of a hif hydroxylase inhibitor
CA2959688C (en) 2014-09-02 2024-02-27 Sunshine Lake Pharma Co., Ltd. Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
US20230190731A1 (en) * 2020-03-17 2023-06-22 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0626178A1 (de) 1993-05-17 1994-11-30 Ciba-Geigy Ag Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen
ATE149486T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
DK0650960T3 (da) 1993-11-02 1997-09-01 Hoechst Ag Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
EP0944619B1 (en) 1996-11-27 2006-10-11 Bristol-Myers Squibb Pharma Company Novel integrin receptor antagonists
GB9707830D0 (en) 1997-04-18 1997-06-04 Smithkline Beecham Plc Novel compounds
AU7526798A (en) 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
EP1379630B1 (en) 2001-03-21 2012-09-26 Isis Innovation Limited Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
US6716866B2 (en) 2001-06-13 2004-04-06 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
US6777425B2 (en) 2001-06-13 2004-08-17 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
CN102552263A (zh) 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
GB0206711D0 (en) 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
EP1644336B1 (en) 2003-06-06 2011-01-19 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
JP2007523870A (ja) 2003-07-15 2007-08-23 メルク　エンド　カムパニー　インコーポレーテッド ヒドロキシピリジンｃｇｒｐ受容体拮抗薬
CA2531796A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2006020133A2 (en) 2004-07-15 2006-02-23 Powerprecise Solutions, Inc. One time operating state detecting method and apparatus
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
AU2006254897A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
ATE470439T1 (de) 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
BRPI0707302B8 (pt) 2006-01-27 2021-05-25 Fibrogen Inc compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
JP2009528279A (ja) 2006-02-16 2009-08-06 ファイブローゲン、インコーポレーテッド 脳卒中を治療するための化合物および方法
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US20110039879A1 (en) * 2007-12-07 2011-02-17 FibroGen ,Inc. Methods for increasing white blood cells
JP6437456B2 (ja) 2013-01-24 2018-12-12 フィブロジェン インコーポレイテッド ｛［１−シアノ−５−（４−クロロフェノキシ）−４−ヒドロキシ−イソキノリン−３−カルボニル］−アミノ｝−酢酸の結晶形態

Also Published As

Publication number Publication date
AU2014209319B2 (en) 2018-04-19
CN105452227A (zh) 2016-03-30
CN105452227B (zh) 2018-05-29
HK1217331A1 (en) 2017-01-06
RU2666144C2 (ru) 2018-09-06
WO2014116849A1 (en) 2014-07-31
KR20150129679A (ko) 2015-11-20
EP2951159A1 (en) 2015-12-09
IL240066B (en) 2019-08-29
US20160002170A1 (en) 2016-01-07
CA2899024A1 (en) 2014-07-31
JP6437456B2 (ja) 2018-12-12
TWI685487B (zh) 2020-02-21
CA2899024C (en) 2022-01-04
AU2014209319A1 (en) 2015-08-27
ES2694297T3 (es) 2018-12-19
DK2951159T3 (en) 2018-11-19
EP2951159B1 (en) 2018-08-22
SG10202009266PA (en) 2020-10-29
US9643928B2 (en) 2017-05-09
RU2015134420A (ru) 2017-03-03
SG11201505748UA (en) 2015-08-28
TW201444800A (zh) 2014-12-01
IL240066A0 (en) 2015-09-24
MX2015009617A (es) 2016-04-20
JP2016505071A (ja) 2016-02-18
KR102233081B1 (ko) 2021-03-29

Similar Documents

Publication Publication Date Title
MX360048B (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
IN2015KN00262A (OSRAM)
MX357906B (es) COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(ß-D-GLU COPIRANOS-1-IL)-BENCENO, MÉTODOS PARA SU PREPARACIÓN Y SU USO PARA PREPARAR MEDICAMENTOS.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
MX2013000009A (es) Procedimiento de preparacion de la sal de l-arginina de perindoprilo.
IN2014MU00455A (OSRAM)
PH12016500577A1 (en) Piperazine derivatives and the use thereof as medicament
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2014141294A3 (en) An improved process for the synthesis of melphalan and the hydrochloride salt
IN2013CH04906A (OSRAM)
MX2016009667A (es) Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma.
HK1212978A1 (zh) 芥子酸的新型衍生物
MX2015015746A (es) Proceso para la preparacion de arformoterol o sal del mismo.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
IN2013MU04056A (OSRAM)
MY181682A (en) Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
IN2013CH04314A (OSRAM)
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
IN2013MU03508A (OSRAM)
IN2014DE01203A (OSRAM)
IN2013CH04330A (OSRAM)
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"
IN2014DN10683A (OSRAM)

Legal Events

Date Code Title Description
FG Grant or registration